Caris Life Sciences: Stronger Fundamentals, Same Conclusion [Seeking Alpha]
Caris Life Sciences, Inc. (CAI)
Last caris life sciences, inc. earnings: 10/29 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
investor.capps.com/investor-relations
Company Research
Source: Seeking Alpha
The Roche partnership validates CAI's discovery platform, opening a new commercial pathway, though near-term revenue impact remains limited. CAI's valuation reset post-lock-up and earnings, now trading at ~10.5x forward EV/Sales, justified by margin expansion but still at a sector premium. Risks remain concentrated in MI revenue dependence, uncertain blood-based program economics, and execution risk given premium valuation; rating remains Hold. Pgiam/iStock via Getty Images My September article on Caris Life Sciences, Inc. ( CAI ) focused more on IPO mechanics than on the company's growth story. Specifically, I was more worried about the 180-day lock-up period that ended on December 15 This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiv
Show less
Read more
Impact Snapshot
Event Time:
CAI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAI alerts
High impacting Caris Life Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
CAI
News
- Caris Life Sciences (NASDAQ:CAI) had its price target raised by analysts at Canaccord Genuity Group Inc. from $28.00 to $30.00. They now have a "hold" rating on the stock.MarketBeat
- The Caris Precision Oncology Alliance Welcomes Providence Swedish Cancer InstitutePR Newswire
- Caris Life Sciences (NASDAQ:CAI) had its "sell (d)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Caris Life Sciences Announces Collaboration with Genentech to Discover Novel Therapeutic Targets in Cancers with High Unmet Clinical Need [Yahoo! Finance]Yahoo! Finance
- Caris Life Sciences Announces Collaboration with Genentech to Discover Novel Therapeutic Targets in Cancers with High Unmet Clinical NeedPR Newswire
CAI
Earnings
- 11/5/25 - Beat
CAI
Sec Filings
- 12/12/25 - Form 4
- 12/12/25 - Form 4
- 12/11/25 - Form 144
- CAI's page on the SEC website